C
C.J.A. Punt
Researcher at Radboud University Nijmegen Medical Centre
Publications - 64
Citations - 2772
C.J.A. Punt is an academic researcher from Radboud University Nijmegen Medical Centre. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 24, co-authored 64 publications receiving 2570 citations.
Papers
More filters
Journal ArticleDOI
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Miriam Koopman,G A M Kortman,Leonie J. M. Mekenkamp,Marjolijn J L Ligtenberg,Nicoline Hoogerbrugge,Ninja Antonini,C.J.A. Punt,J.H.J.M. van Krieken +7 more
TL;DR: It is concluded that dMMR is rare in patients with sporadic advanced CRC, which supports the hypothesis that d MMR tumours have a reduced metastatic potential, as is observed in d MMRR patients with early stage disease.
Journal Article
Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Andreas O. Eggert,M.W.J. Schreurs,O.C. Boerman,Wim J.G. Oyen,A.J. de Boer,C.J.A. Punt,Carl G. Figdor,Gosse Jan Adema +7 more
TL;DR: It is demonstrated that optimal induction of antitumor reactivity against the autologous melanocyte differentiation antigen tyrosinase-related protein-2-derived peptide-loaded DC vaccination occurs after s.c. vaccination and correlates with the preferential accumulation of DCs in the T-cell areas of lymph nodes.
Journal ArticleDOI
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
Nikki Knijn,Leonie J. M. Mekenkamp,M Klomp,M E Vink-Börger,Jolien Tol,Steven Teerenstra,Jos W. R. Meijer,M Tebar,S Riemersma,J.H.J.M. van Krieken,C.J.A. Punt,Iris D. Nagtegaal +11 more
TL;DR: Both primary tumours and liver metastases can be used for KRAS mutation analysis, and the concordance of test results between primary tumour and corresponding metastases is high.
Journal ArticleDOI
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
Jolien Tol,Miriam Koopman,M. C. Miller,Arjan G.J. Tibbe,Annemieke Cats,Geert-Jan Creemers,A. Vos,Iris D. Nagtegaal,Leon W.M.M. Terstappen,C.J.A. Punt +9 more
TL;DR: The CTC count before and during treatment independently predicts PFS and OS in ACC patients treated with chemotherapy plus targeted agents and provides additional information to CT imaging.
Journal ArticleDOI
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Jolien Tol,Miriam Koopman,C.J. Rodenburg,Annemieke Cats,Geert Jan Creemers,J. G. Schrama,Frans L. G. Erdkamp,A. Vos,Linda Mol,Ninja Antonini,C.J.A. Punt +10 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible.